Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu-177 FAPI-09
- Development stage
- Unknown
- Lead developer
- Aster International Institute of Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Lu-177 FAPI-09 is a therapeutic radiopharmaceutical designed to target fibroblast activation protein (FAP), an enzyme highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of various solid tumors. The agent consists of the FAPI-09 ligand, a small molecule/peptide derivative, chelated to the beta-emitting radioisotope Lutetium-177. This theranostic approach allows for the selective delivery of cytotoxic radiation to the tumor stroma, potentially disrupting the supportive environment of the tumor and sensitizing it to other treatments. It is primarily investigated for advanced, chemotherapy-resistant malignancies, including gastrointestinal and ovarian cancers, often in combination with chemotherapy or immunotherapy.
- Other names
- Lutetium-177 FAPI-09Lutetium177 FAPI-09Lutetium 177 FAPI-09[177Lu]Lu-FAPI-09
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on Lu-177 FAPI-09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu-177 FAPI-09.